The Application dimension of the PEGylated Drugs market is partitioned into five primary categories: Oncology, Hematology, Infectious Diseases, Rare Diseases, and Other therapeutic areas. Oncology dominates the landscape, accounting for roughly 45 % of total revenue, driven by the high demand for long‑acting monoclonal antibodies such as pegylated liposomal doxorubicin. Hematology follows with an estimated 25 % share, reflecting the adoption of PEG‑modified factor VIII and IX products that extend half‑life and reduce infusion frequency for hemophilia patients. Infectious Diseases contributes about 15 % of the market, where PEGylated interferons and antiviral enzymes improve pharmacokinetics and patient compliance. Rare Diseases represent 10 % of sales, largely supported by orphan‑drug designations for PEGylated enzymes treating lysosomal storage disorders. The residual 5 % classified as Other encompasses ophthalmology, cardiology, and veterinary uses. Collectively, these application segments shape the overall PEGylated Drugs market size, with each segment’s growth rate reflecting disease prevalence, reimbursement policies, and pipeline intensity. Analysts project that the oncology share will decline to 42 % by 2030 as biosimilar competition intensifies, while hematology and rare disease segments are expected to expand at CAGR rates of 7 % and 9 %.
